Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors

Summary

This study is a multi center, open label, dose increasing/dose expanding/efficacy expanding phase I clinical trial aimed at evaluating the safety, tolerance, PK characteristics, and anti-tumor efficacy characteristics of HRS-2189 single drug in patients with advanced malignant solid tumors. This study was divided into three stages: dose escalation, dose expansion, and efficacy expansion.

Timeline

Start

2023-05-26

Primary completion

2025-12-31

Completion

2025-12-31

Drugs

Indications